当前位置: X-MOL 学术Expert Opin. Biol. Ther. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Avelumab: search for combinations of immune checkpoint inhibition with chemotherapy
Expert Opinion on Biological Therapy ( IF 4.6 ) Pub Date : 2020-10-03 , DOI: 10.1080/14712598.2021.1825679
Gerhard Hamilton 1
Affiliation  

ABSTRACT

Introduction

Immune checkpoint inhibition (ICI) has proved successful for selected tumors and a subpopulation of patients. The human monoclonal IgG1 antibody (mAB) avelumab capable of mediating antibody-dependent cytotoxicity (ADCC) lysis is directed to programmed death ligand-1 (PD-L1) of tumor cells and is tested in trials aiming to improve ICI in combination with chemotherapeutic drugs.

Areas covered

This article presents an overview of the current trials to enhance ICI regimens using avelumab in combination with chemotherapeutics, antiangiogenetic drugs, and immunomodulators. Predictive factors for this kind of immunochemotherapy are discussed.

Expert opinion

Clinical data demonstrate that avelumab shows efficacy in cancer patients against Merkel cell carcinoma (MCC), renal cell carcinoma (RCC), and urothelial cancers as single agent. Furthermore, avelumab in combination with axitinib in RCC increases survival and exhibits activity in combination with docetaxel in urothelial carcinoma. However, several other immunochemotherapy trials for ovarian cancer, gastric cancer, and non-small lung cancer (NSCLC) showed no activity due to factors disfavoring administration of immunotherapy combos.



中文翻译:

Avelumab:寻找免疫检查点抑制与化疗的组合

摘要

介绍

免疫检查点抑制 (ICI) 已被证明对选定的肿瘤和患者亚群是成功的。能够介导抗体依赖性细胞毒性 (ADCC) 裂解的人单克隆 IgG1 抗体 (mAB) avelumab 针对肿瘤细胞的程序性死亡配体-1 (PD-L1),并在旨在与化疗药物联合改善 ICI 的试验中进行测试.

涵盖的领域

本文概述了当前使用 avelumab 联合化疗、抗血管生成药物和免疫调节剂来增强 ICI 方案的试验。讨论了这种免疫化疗的预测因素。

专家意见

临床数据表明,avelumab 在癌症患者中显示出对默克尔细胞癌 (MCC)、肾细胞癌 (RCC) 和尿路上皮癌的单药疗效。此外,avelumab 与阿昔替尼联合治疗 RCC 可提高生存率,并与多西紫杉醇联合治疗尿路上皮癌可提高存活率并表现出活性。然而,其他几项针对卵巢癌、胃癌和非小细胞肺癌 (NSCLC) 的免疫化学疗法试验由于不利于免疫疗法组合给药的因素显示没有活性。

更新日期:2020-10-03
down
wechat
bug